Top-Analysts PicksInvest alongside the top 15% of Wall Street analysts.

Try Top-Picks
BioAtla, Inc. Banner

BioAtla, Inc.

BCAB Stock Analysis

Page title

Section title

About BioAtla, Inc.

Biotechnology
Healthcare

BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and ovarian cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California.

BioAtla, Inc. Key Metrics

Market Cap
$76M
52 Weeks Low
$1.14
52 Weeks High
$4.02
P/B
3.30x
P/E
-0.93x
P/S
5.97x

Upcoming Events

    BCAB Analyst Forecasts

    ‌
    ‌

    BCAB Financials

    BCAB Income Statement Key Metrics

    • Revenue(TTM)12.71 M
    • Gross Profit(TTM)11.87 M
    • EBITDA(TTM)-85.40 M
    • Net Income(TTM)-81.82 M
    • EPS Diluted(TTM)-1.7000000000000002

    Decode BCAB's Latest Earnings Call with Ease

    Tap 'Generate' for a crystal-clear,
    AI-crafted summary and stay ahead in the investment game!

    BCAB earnings and revenue history

    BCAB Return on Equity

    See how efficiently BCAB generates profit for it's shareholders.

    -174.70%

    10
    0
    100

    1. Poor

    2. Average

    3. Strong

    Return on Equity vs Peers

    Return on Equity ratio of BCAB (-1.747) is lower than the average of its peers (-0.372).

    Return on Equity Growth

    BCAB's Return on Equity has shown poor growth over the past 10 years, increasing by only -9.42%.

    BCAB Revenue Growth

    See how BCAB has grown it's revenue over the past 10 years.

    ‌

    Revenue Growth

    BCAB's revenue has shown poor growth over the past 10 years, increasing by only -100%.